Skip to main content
Clinical Trials/NCT01544530
NCT01544530
Terminated
Phase 2

Feasibility of Mild-to-moderate Therapeutic Hypothermia as an In-vivo Organ Preservation Strategy in Brain-dead Donors

University of Pittsburgh1 site in 1 country4 target enrollmentMarch 2012

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Organ Transplantation From Brain-dead Donors
Sponsor
University of Pittsburgh
Enrollment
4
Locations
1
Primary Endpoint
Feasibility and safety
Status
Terminated
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to assess the feasibility and safety of mild-to-moderate hypothermia as an in-vivo organ preservation strategy compared to normothermia in 60 brain-dead organ donors.

Registry
clinicaltrials.gov
Start Date
March 2012
End Date
March 2014
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Raghavan Murugan

Associate Professor

University of Pittsburgh

Eligibility Criteria

Inclusion Criteria

  • Age greater than 18 years;pronounced dead as per hospital brain-death criteria
  • Accepted by organ procurement organization for organ donation
  • Subjects within 3 hours of brain death pronouncement

Exclusion Criteria

  • Consent cannot be obtained from authorized representative;mean arterial pressure \< 60 mmHg and/ or more than 2 vasopressor and/or inotrope use
  • Presence of 2nd or 3rd degree heart block
  • Ongoing extracranial hemorrhage
  • International normalized ratio \> 3.0
  • Donors with human-immunodeficiency virus infection
  • Pregnancy

Outcomes

Primary Outcomes

Feasibility and safety

Time Frame: From enrollment to organ procurement (average of 24 hours)

Brain-dead organ donors will be followed from study enrollment up to organ procurement for an average of 24 hours

Secondary Outcomes

  • Interleukin-6(Baseline, 6 hours, and at organ procurement (15-24 hrs))
  • Actual no. of organs transplanted(At the time of organ procurement)
  • Death receptor-5(Baseline, 6 hours, and at organ procurement (15-24 hrs))
  • Six-month hospital free survival in recipients(6 months)
  • Malondialdehyde(Baseline, 6 hours, and at organ procurement (15-24 hrs))
  • Urinary isoprostanes(Baseline, 6 hours, and at organ procurement (15-24 hrs))
  • lactate(Baseline, 6 hours, and at organ procurement (15-24 hrs))

Study Sites (1)

Loading locations...

Similar Trials